Clinical Trial Update: Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and tolerability of OPN-6602 in subjects with relapsed or refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• OPN-6602

Snippet

Sponsor: Opna Bio LLC | Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING